News
Get access to our breaking news, and company information
Press Releases
Pillar Biosciences Partners with AstraZeneca to Help Accelerate Access to Liquid Biopsy Testing
Partnership aims to make liquid biopsy tumor profiling more accessible to local laboratories, clinicians and patients through rapid, affordable, kitted NGS testing solutions. Natick, MA
Pillar Biosciences Launches oncoReveal™ Nexus To Help Accelerate the Delivery of Targeted Therapy
Natick, MA – August 27, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the global launch of oncoReveal™ Nexus, a research-use-only (RUO) next-generation sequencing (NGS)
Pillar Biosciences’ FDA Approved Solid Tumor NGS Kit oncoReveal™ CDx Launched at Molecular Pathology Laboratory Network, Inc.
Natick, MA – July 30, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced that Molecular Pathology Laboratory Network, Inc., (MPLN) is now the
Pillar Biosciences oncoReveal™ CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the Illumina MiSeq™Dx System
Company continues to execute on its global strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing Natick, MA – April
Pillar Biosciences to Present at NYBIO | NYSE Life Science Company Showcase on December 14th
Natick, MA – December 7, 2023 – Pillar Biosciences is pleased to announce that Randy Pritchard, Chief Executive Officer, and Vincent Ricci, Chief Financial Officer,
Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting
NATICK, Mass. – November 8, 2023 – (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators